SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
El-Hibri Fuad
(Last) (First) (Middle)
400 PROFESSIONAL DRIVE, SUITE 400
(Street)
GAITHERSBURG MD 20879
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chairman
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2020
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/09/2020 M(1) 20,000 A $26.45 1,143,988 D
Common Stock 11/09/2020 S(1) 20,000 D $95.26(2) 1,123,988 D
Common Stock 11/10/2020 M(1) 19,391 A $26.45 1,143,379 D
Common Stock 11/10/2020 S(1) 19,391 D $88.21(3) 1,123,988 D
Common Stock 2,140,463(4) I By Intervac, L.L.C.
Common Stock 1,524,155(5) I By Biovac, L.L.C.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $26.45 11/09/2020 M(1) 20,000 (6) 03/09/2022 Common Stock 20,000 $0.00 19,391 D
Stock Options (Right to Buy) $26.45 11/10/2020 M(1) 19,391 (6) 03/09/2022 Common Stock 19,391 $0.00 0 D
Explanation of Responses:
1. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.85 to $98.49. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.69 to $90.00. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. Intervac, L.L.C. ("Intervac") is the direct owner of 2,140,463 shares of the Issuer's common stock. The Reporting Person serves as the managing member of Intervac and the Reporting Person or his wife serve as the trustee of each of the members of Intervac. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
5. The Reporting Person, individually, and the Reporting Person and his wife, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C., which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
6. The options vested in three equal installments on March 9 2016, March 9, 2017 and March 9, 2018.
Remarks:
/s/ Carl A. Valenstein, attorney-in-fact 11/12/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.